REG - IXICO plc - Board Appointment

IXICOAnnouncement

05/08/2024 07:00

For best results when printing this announcement, please click on link below:
http://newsfile.refinitiv.com/getnewsfile/v1/story?guid=urn:newsml:reuters.com:20240805:nRSE0599Za&default-theme=true

RNS Number : 0599Z  IXICO plc  05 August 2024

5 August 2024

 

IXICO plc

 

("IXICO" or the "Company")

 

Appointment of CEO

 

IXICO plc (AIM: IXI), the precision analytics company delivering intelligent
insights in neuroscience, is pleased to announce that Bram Goorden will be
appointed as Chief Executive Officer of the Company from 19 August 2024.

 

Bram has over 20 years leadership experience in BioPharma and precision
medicine, serving in roles where he has been instrumental in shaping
commercial strategies for scale, growing revenues and ultimately enabling
realisation of shareholder value. He has strong CNS experience, and
established networks within IXICO's target market bringing sector relevant
strength to IXICO.

 

Bram joins having recently held C-level roles at Eagle Genomics Limited where
he drove key industry alliances for their AI platform and NASDAQ listed SOPHiA
Genetics Inc where he expanded their US footprint and delivered key alliances
with Pharma. In previous roles as VP International Business, he expanded
Foundation Medicine Inc's global presence in precision medicine including
programs with major BioPharma partners, and as division CEO of US-based
Prometheus Laboratories he delivered shareholder value via the integration of
the company into Nestle Health Science SA. Bram has also held senior
management positions within UCB Pharma SA and Eli Lilly & Co, both in the
field of CNS medicine.

 

Bram's neuroscience experience is demonstrated at Board level through current
and past roles at Mantis Photonics AB, a company providing a non-invasive
method of detecting neuro-degenerative diseases through retinal image
biomarker analysis and Cerecin Inc, a clinical development company focused on
therapeutic approaches to treat neurodegenerative diseases. Bram started his
career as a management consultant at Accenture.

 

Bram's appointment follows the announcement made on 12 January 2024, of Giulio
Cerroni's intention to retire from his role as CEO by the end of 2024. Giulio
will step down as a director of the Company on 16 August 2024. Giulio
continues to be available to the Company to support an orderly hand over.

 

Mark Warne, Chair of the Board, commented: "I am delighted to welcome Bram to
the Board as our CEO. Bram has significant track record in the commercial
application of AI precision medicine solutions that is complemented by
technical knowledge within neurodegenerative diseases.  As IXICO looks to
return to growth, Bram's experiences provide excellent credentials to ensure
IXICO also realises shareholder value.

I would like to thank Giulio for his valuable contributions over many years.
Having joined IXICO in 2017, Giulio steered the company through a period of
both strong growth and more challenging trading conditions.  He has overseen
the development of the company's science and technology portfolio which, in
combination with IXICO's operational capabilities, ensure the consistent
delivery of leading services to the CNS clinical trials market."

 

Further disclosures required under the AIM Rules

 

In addition to his appointment to the Ixico Board, Bram Goorden, aged 50,
holds or has held the following directorships or partnerships in the past five
years. Bram currently holds no shares in the Company.

 

 Current              Previous
 Oncobit AG           SOPHIA Genetics SA
 Mantis Photonics AB  SOPHIA Genetics Inc
                      De Bonte Leeuw Inc

 

For further information please contact:

 

 IXICO plc                                                                         +44 (0) 20 3763 7499
 Giulio Cerroni, Chief Executive Officer

 Grant Nash, Chief Financial Officer

 Cavendish Capital Markets Limited (Nominated Adviser and                          +44 (0) 20 7220 0500

 Sole Broker)
 Giles Balleny / Dan Hodkinson (Corporate Finance)

 Nigel Birks/Harriet Ward (Corporate Broking)

 Michael F Johnson / Tamar Cranford Smith (Sales)

 

 

 

About IXICO

 

IXICO is dedicated to delivering insights in neuroscience to help transform
the advancement of investigational therapies for neurological diseases, such
as Huntington's disease, Parkinson's disease and Alzheimer's disease. The
Company's purpose is to advance medicine and human health by turning data into
clinically meaningful information, providing valuable new insights in
neuroscience by supporting pharmaceutical companies across all phases of CNS
clinical research. IXICO's goal is to be a leading advocate of artificial
intelligence in medical image analysis.

 

IXICO has developed and deployed breakthrough data analytics, at scale,
through its remote access technology platform, to improve the return on
investment in drug development and reduce risk and uncertainty in clinical
trials for the Company's pharmaceutical clients.

 

More information is available on www.IXICO.com (http://www.ixico.com/)  and
follow us on Twitter @IXICOnews

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com (mailto:rns@lseg.com)
 or visit
www.rns.com (http://www.rns.com/)
.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our
Privacy Policy (https://www.lseg.com/privacy-and-cookie-policy)
.   END  BOABLGDIDDGDGSD